Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8937948 | 0.92 | ROCK1 (0.52) | MAP2K1MEN1KMT2ACYP2A13ROCK1 | |
| SCHEMBL8938694 | 0.90 | MAP2K1 (0.54) | MAP2K1MEN1KMT2AROCK1OPRM1 | |
| SCHEMBL8938278 | 0.89 | MAP2K1 (0.59) | MAP2K1ROCK1MCHR1OPRM1ROCK2 | |
| SCHEMBL8934795 | 0.86 | ROCK1 (0.55) | ROCK1EPHX2CYP2C9CYP2J2ROCK2 | |
| SCHEMBL8934996 | 0.86 | MAP2K1 (0.58) | MAP2K1ROCK1MCHR1ROCK2 | |
| SCHEMBL8938119 | 0.85 | MAP2K1 (0.55) | MAP2K1SIGMAR1MCHR1OPRM1 | |
| SCHEMBL8934981 | 0.85 | MAP2K1 (0.59) | MAP2K1ROCK1ROCK2 | |
| SCHEMBL8935044 | 0.85 | MAP2K1 (0.57) | MAP2K1MEN1KMT2AROCK1SIGMAR1 | |
| SCHEMBL8939156 | 0.84 | ROCK1 (0.52) | MAP2K1MEN1KMT2AROCK1OPRM1 | |
| SCHEMBL12211847 | 0.83 | MAP2K1 (0.55) | MAP2K1ROCK1EPHX2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385047-B1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | MAP2K1 1916/4885MEN1 4354/4885KMT2A 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.